Condition: Geographic Atrophy Secondary to Age-related Macular Degeneration · Sponsor: ADARx Pharmaceuticals, Inc.
Phase 2 study is designed to assess the efficacy of ADX-038 compared with placebo in participants with GA secondary to AMD. Safety, pharmacokinetics (PK), and pharmacodynamics (PD) will also be assessed.
This description comes directly from the study's public registry record.
Nali Castillo · 877-232-7974 · info@adarx.com
Always discuss trial participation with your own doctor first.
| ADARx Clinical Site | Gilbert, Arizona, United States | Recruiting |
| ADARx Clinical Site | Phoenix, Arizona, United States | Recruiting |
| ADARx Clinical Site | Bakersfield, California, United States | Recruiting |
| ADARx Clinical Site | Beverly Hills, California, United States | Recruiting |
| ADARx Clinical Site | Huntington Beach, California, United States | Recruiting |
| ADARx Clinical Site | Poway, California, United States | Recruiting |
| ADARx Clinical Site | Orlando, Florida, United States | Recruiting |
| ADARx Clinical Site | Wildwood, Florida, United States | Recruiting |
| ADARx Clinical Site | Hagerstown, Maryland, United States | Recruiting |
| ADARx Clinical Site | Reno, Nevada, United States | Recruiting |
| ADARx Clinical Site | Erie, Pennsylvania, United States | Withdrawn |
| ADARx Clinical Site | Austin, Texas, United States | Recruiting |
+ 15 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06990269